LA ROCHELLE, France, February 24, 2022–(BUSINESS WIRE)–Regulatory news:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/PME eligible), a Research and Development company committed to scientific innovation to prevent and combat metabolic diseases, today presents its 2022 financial communication calendar.
March 15: 2021 Annual Report
May 5: General Meeting (participation details to be specified later)
September 30: 2022 half-year report
All financial information concerning Valbiotis, such as financial reports, general meetings, stock market data, letters to shareholders, presentations or registration documents are available on the Company’s website, in the “Investors” section.
Valbiotis is a Research & Development company committed to scientific innovation to prevent and combat metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize health by developing a new class of health nutrition products intended to reduce the risk of major metabolic diseases, based on a multi-target strategy enabled by the use of plant resources. land and sea.
Its products are intended to be licensed to players in the health sector.
Created in early 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has set up three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec (Canada).
Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has also obtained the status of “Young Innovative Company” and has received significant financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a company eligible for PEA-PME.
For more information on Valbiotis, visit: www.valbiotis.com
ISIN Code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational assumptions and on the information available to Valbiotis to date. However, this does not in any way constitute a guarantee of future performance, and these projections may be affected by changes in economic and financial market conditions, as well as by certain risks and uncertainties, in particular those described in the Universal Registration Document. of Valbiotis approved by the Autorité des marchés financiers (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com). This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation to buy or subscribe to shares or financial securities of Valbiotis in any country whatsoever.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220223005880/en/
Corporate communication / Valbiotis
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
Financial communication / Actifin
+33 1 56 88 11 14